We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Argenx has released positive results from a late-stage trial of Vyvgart (efgartigimod alfa-fcab) for the subcutaneous treatment of patients with generalized myasthenia gravis. Read More
Moderna says that it’s expanding its messenger RNA (mRNA) vaccine pipeline to include mRNA-1230, a triple-combination respiratory vaccine candidate to protect against COVID-19, influenza and respiratory syncytial virus (RSV), and mRNA-1287, a vaccine candidate that will target four endemic human coronaviruses (HCoVs). Read More
Deep decreases from high baseline tau levels were associated with the best clinical response in patients who responded to Aduhelm during clinical trials, according to new data presented at the Alzheimer’s Disease/Parkinson’s Disease 2022 international conference last week in Barcelona, Spain. Read More
Moderna and Pfizer/BioNTech are both pushing to get expanded Emergency Use Authorization (EUA) for a fourth dose/second booster of their COVID-19 vaccines, but a new study questions its effectiveness in the population at large. Read More
Merck’s mega blockbuster Keytruda (pembrolizumab) may soon have a new indication, this time in an earlier stage of disease than is typical for the anti-PD-L1 therapy. Read More
Diversity is a critical area in clinical research that desperately needs to be improved, the pharma industry agrees, but policies that would require sponsors to enroll more diverse populations will backfire, contends industry trade group PhRMA. Read More
Esai’s investigational anti-tau antibody E2841 grabbed some air time yesterday in Barcelona, Spain, with the first detailed look at a phase 2/3 study in people who are genetically predestined to develop Alzheimer’s disease. Read More
The FDA approved Evrysdi to treat patients two months and older with Type 1 spinal muscular atrophy in August 2020, making it the first oral drug approved to treat the disease. Read More
Patients treated with Aduhelm experienced decreased levels of tau — the second dysregulated protein in Alzheimer’s disease — which were associated with a slowing of cognitive decline, Biogen executive Samantha Budd Haeberlein said yesterday at the AD/PD 2022 meeting on Alzheimer’s disease and Parkinson’s disease in Barcelona, Spain, March 15-20. Read More